This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 i…

HER2 Mutation-Related TumorsHER2HER2-positive Breast Cancer+10 more

~Estimated

~$10 – $8,750

Iambic Therapeutics, IncNCT06253871

Evaluating Biomarkers of Cognitive Dysfunction in Patients With Cancer

This study investigates the effects of brain radiotherapy on cognitive function by evaluating plasma biomarkers and apolipoprotein E (APOE) genotype in patient…

Brain Tumor AdultBrain Metastases From Solid TumorsBrain Tumor, Primary+1 more

~Estimated

~$10 – $675

University of California, San FranciscoNCT07226466

Phase 1

A Phase 1, Open-Label, Dose-escalation and Dose-Expansion Study Evaluating AO-252, a Protein-Protein Interaction Inhibitor of TACC3, in Patients With Advanced Solid Tumors With or Without Brain Metastases

The purpose of this study is to assess the safety, tolerability and efficacy of the study drug AO-252 and identify the best dose for use in future studies.

Solid Tumor MalignanciesBrain Metastases From Solid Tumors

~Estimated

~$10 – $8,750

A2A Pharmaceuticals Inc.NCT06136884